Oslo, 20 October 2023. Lytix Biopharma - Lytix Biopharma AS ("Lytix") (Euronext
Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that
Øystein Rekdal, Chief Executive Officer, and Graeme Currie, Chief Development
Officer, will host a webcast for investors and analysts on Monday October 23 at
15:30 CET, in conjunction with the ESMO 2023 Congress. 

The webcast is being held to provide further insights and additional information
about the preliminary data from the ATLAS-IT-05 study, that is being presented
in a poster session at ESMO, and the associated press release issued by Lytix
Biopharma on Monday October 23.
 
The webcast and subsequent Q&A session will be held in English and may be viewed
live by registering here: https://forms.office.com/e/aiR9KtDQKL

ATLAS-IT-05 is a Phase II open label clinical trial with LTX-315 in combination
with Keytruda® (pembrolizumab) in stage III-IV melanoma patients refractory to
treatment with PD-1 / PD-L1.  

***

For more information, please contact: 
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
Ole Peter Nordby, Head of IR & Communications Manager:
ole.peter.nordby@lytixbiopharma.com
Optimum Strategic Communications: Jonathan Edwards, Vici Rabbetts:
lytix@optimumcomms.com


Lytix in brief: 
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
Company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class molecule representing a new and
superior therapeutic principle to kill cancer cells and boost anti-cancer
immunity, with the potential to be the ideal combination partner with other
types of immunotherapy. LTX-315 targets cancer cells and disintegrates their
cell membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens.  This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors
including PBM Capital, a US based, healthcare-focused investment firm.